| Theme | Pathophysiology and Treatment of Deranged Lipid Metabolism in Chronic Renal Failure | |
|---|---|---|
| Title | Clinical features of hyperlipidemia -- Lipoprotein metabolism in the patients treated with CAPD | |
| Publish Date | 1998/09 | |
| Author | Hideaki Kurata | Department of Internal Medicine III, The Jikei University School of Medicine |
| Author | Kanae Shimizu | Department of Internal Medicine III, The Jikei University School of Medicine |
| Author | Kazunori Utsunomiya | Department of Internal Medicine III, The Jikei University School of Medicine |
| Author | Masaaki Nakayama | Department of Internal Medicine II, The Jikei University School of Medicine |
| Author | Hitoshi Kubo | Department of Internal Medicine III, The Jikei University School of Medicine |
| Author | Naoko Tajima | Department of Internal Medicine II, The Jikei University School of Medicine |
| Author | Yoshindo Kawaguchi | Department of Internal Medicine II, The Jikei University School of Medicine |
| [ Summary ] | Plasma lipoprotein profiles in uremic patients treated with CAPD are characterized by decreases in HDL-C levels, and increases in LDL-C, VLDL-C and TG levels especially with type III and IV hyperlipoproteinemia. This dyslipoproteinemia is considered to be caused by the continuous loading of glucose in the dialisate through the peritoneum. However, in our study, there were no significant changes in levels of plasma HDL-C, VLDL-C or TG before or after six months of receiving CAPD treatments. This data suggests that dyslipoproteinemia in CAPD patients depends not only on the glucose loading but also their genetic history. On the other hand, dyslipoproteinemia including an increase in remnant TG levels, may be found in the CAPD patients without hyperlipidemia. So, we need further evaluation of the relationship between the increase in remnant TG levels and atherogenesis in CAPD patients. | |